In a more recent study, Ritterhouse et al. confirmed that tumors with homologous recombination deficiency, including those diagnosed in BRCA1 and BRCA2 mutation carriers, are six times more likely to exhibit non-classical (SET or ambiguous) features of high-grade serous carcinoma (50). This evidence concerns the gene BRCA2 and serous adenocarcinoma.